Data cannot be shared publicly because of the data are owned by a third party (Taiwan National Health Insurance(NHI)) and authors do not have permission to share the data. The authors had no special privileges in accessing the data. Data are available from the Taiwan NHI Institutional Data Access / Ethics Committee for researchers who meet the criteria for access to confidential data. The data underlying the results presented in the study are available from he Longitudinal Health Insurance Database 2005 (LHID 2005), which was released by Taiwan NHI for research purposes (<https://nhird.nhri.org.tw/en/Data_Subsets.html>). Data access requests can be sent to project undertaker (email: <nhird@nhri.edu.tw>) and to the Taiwan NHI.

Introduction {#sec005}
============

An inguinal hernia (IH) is a protrusion of abdominal-cavity contents, such as intestines, through the inguinal canal \[[@pone.0234329.ref001]\]. Some patients are not bothered by annoying symptoms, such as a protruding non-painful mass, so a clinician might choose conservative treatments \[[@pone.0234329.ref002]--[@pone.0234329.ref004]\]. However, more serious symptoms may appear in about 66% of affected people \[[@pone.0234329.ref001]\], and these might include discomfort or pain especially with lifting, exercise, coughing or bowel movements \[[@pone.0234329.ref005]\]. The most terrible event is that intestines are trapped and pinched in the groin or scrotum and cannot be moved back into the abdomen, leading to an incarcerated or even strangulated inguinal hernia. This usually produces severe pain and tenderness of the area and the strangulation of intestines, where the blood supply to part of the intestine is blocked, possibly resulting in bowel perforation \[[@pone.0234329.ref006]\] or gangrene \[[@pone.0234329.ref007]\]. It is life-threatening and needs emergent surgery \[[@pone.0234329.ref008]\].

Risk factors for the development of an IH include inheritance \[[@pone.0234329.ref009]\], gender \[[@pone.0234329.ref010]\], age \[[@pone.0234329.ref011]\], collagen metabolism \[[@pone.0234329.ref012]\], chronic cough \[[@pone.0234329.ref013]\], chronic constipation \[[@pone.0234329.ref013]\], and prostatectomy history, especially in retropubic open prostatectomy \[[@pone.0234329.ref001]\]. Conversely, obesity decreases the occurrence of inguinal hernia \[[@pone.0234329.ref014]\]. There are several mechanisms for IH, such as musculo-fascial weakness \[[@pone.0234329.ref015]\], anatomical variations \[[@pone.0234329.ref016]\], connective tissue alterations \[[@pone.0234329.ref017], [@pone.0234329.ref018]\] and high intra-abdominal pressure \[[@pone.0234329.ref019]\]. A study with a large population (1.5 million subjects) indicated that increased cumulative intra-abdominal pressure, like lifting, standing and walking, is related to the formation of IH \[[@pone.0234329.ref020]\]; furthermore, reducing daily cumulative intra-abdominal pressure could prevent IH surgery by 30% \[[@pone.0234329.ref021]\].

Benign prostatic hyperplasia (BPH) is one of the most common causes of male lower urinary tract symptoms (LUTS) and occurs with aging \[[@pone.0234329.ref022]\]. As LUTS-BPH progresses despite medical treatment, post void residual (PVR) and urinary tract infection can be identified requiring appropriate surgical intervention \[[@pone.0234329.ref023]\]. For a urologist, it is not uncommon to discover the coexistence of inguinal hernia and symptomatic BPH. In 1982, while performing transurethral resection of the prostate, Thompson et al. disclosed inguinal hernia in 20% of men with LUTS-BPH \[[@pone.0234329.ref024]\]. However, we were unable to confirm the association between LUTS-BPH and IH through the previous reports \[[@pone.0234329.ref025], [@pone.0234329.ref026]\]. The aim of this study was to examine the association between LUTS-BPH and IH in a nationwide population-based cohort study.

Material and methods {#sec006}
====================

Data source {#sec007}
-----------

The Taiwan National Health Insurance (NHI) scheme covers 99% of the population in Taiwan \[[@pone.0234329.ref027]\]. A database, the Longitudinal Health Insurance Database 2005 (LHID 2005), was released by Taiwan NHI for research purposes \[[@pone.0234329.ref028]\]. The LHID2005 includes about 1 million beneficiaries drawn randomly from a total of 23 million individuals in the NHI registry of 2005. This database contains all the medical claims of individuals enrolled from 1997 to 2013, and was proven to be statistically identical to the whole population of 23 million individuals in gender distribution (<http://nhird.nhri.org.tw/en/Data_Subsets.html>). The diagnoses in the LHID 2005 are coded on the basis of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The data from LHID2005 is de-identified and encrypted for patient protection. Ethical approval for the study was provided by the Institutional Review Board of Kaohsiung Medical University Hospital (number KMUHIRB-E(I)-20190325).

Study cohort and information collection {#sec008}
---------------------------------------

This is a population-based cohort study, including men with LUTS-BPH and a matched comparison cohort of men without LUTS-BPH. All medical claims of men aged 20 and above from 1997--2013 year were collected. We used the ninth revision of the International Classification of Diseases (ICD9) codes 600.XX to identify LUTS-BPH. A diagnosis of LUTS-BPH was based on the clinical symptoms and/or digital examinations by physicians. The date of the first medical visit due to LUTS-BPH was defined as the index date. IH was identified by ICD9 diagnostic codes (ICD9 550.1, 550.1 and 550.9). Men in the comparison cohort were randomly selected from the LHID 2005 and matched to men with LUTS-BPH by age at a 1:1 ratio. Age and past history of hypertension (ICD9 401--405), kidney disease (ICD9 585, 588), diabetes (ICD9 250), liver disease (ICD 570, 571), obesity (ICD9 278), chronic obstructive pulmonary disease (ICD9 491--493, 496) and urethral disease (ICD9 598) were collected for men with and without LUTS-BPH. Subjects younger than 20 years of age, who had received radical prostatectomy (NHI surgical orders codes: 79403B and 79410B) and had been diagnosed with IH before the index date were excluded.

Statistical analysis {#sec009}
--------------------

All men were followed from the date of diagnosis until death, emigration or end of follow-up (31 December 2013), whichever event came first. Statistical analyses were performed using SPSS software, version 20.0 (SPSS Inc., Chicago, IL). Percentages were calculated for categorical variables. Chi-square test or Fisher's exact test were used to analyze the differences between categorical variables. Baseline characteristics such as age and selected comorbidities were considered risk factors for the diagnosis of IH. We included hypertension \[[@pone.0234329.ref029]\], kidney disease \[[@pone.0234329.ref030]\], diabetes mellitus \[[@pone.0234329.ref031]\], liver disease \[[@pone.0234329.ref032]\], obesity \[[@pone.0234329.ref033]\], chronic obstructive pulmonary disease \[[@pone.0234329.ref034]\] and urethral disease \[[@pone.0234329.ref035]\] as potential confounders. Log-rank tests were used to compare differences in the cumulative incidence of IH between men with and without LUTS-BPH. Cox proportional hazards regression models were applied to estimate hazard ratios (HRs) and 95% confidence interval (CI) for subsequent IH, while controlling for the above-mentioned potential confounders. A two-tailed p value of 0.05 or less was considered statistically significant.

Results {#sec010}
=======

This study included 22,310 men diagnosed with LUTS-BPH and 22,310 matched comparison men without LUTS-BPH. [Table 1](#pone.0234329.t001){ref-type="table"} shows the age and comorbidity distributions of all men. Most individuals in our study aged 40 years or above. No significant differences in age and comorbidities were found between men with and without LUTS-BPH.

10.1371/journal.pone.0234329.t001

###### Demographic data (N = 44,620).

![](pone.0234329.t001){#pone.0234329.t001g}

                           LUTS-BPH(-) (n = 22,310)   LUTS-BPH(+) (n = 22,310)                    
  ------------------------ -------------------------- -------------------------- ------- -------- ---------
  Age                                                                                             
  \<40                     696                        (3.1)                      699     (3.1)    0.359
  40--59                   10627                      (47.6)                     10513   (47.1)   
  \> = 60                  10987                      (49.2)                     11098   (49.7)   
  Comorbidities                                                                                   
  Diabetes                 4255                       (19.1)                     4264    (19.1)   0.914
  Hypertension             9840                       (44.1)                     9819    (44.0)   0.841
  Chronic kidney disease   2123                       (9.5)                      2125    (9.5)    0.974
  Liver disease            4532                       (20.3)                     4454    (20.0)   0.357
  Obesity                  133                        (0.6)                      123     (0.6)    0.531
  COPD                     7642                       (34.3)                     7641    (34.2)   0.992
  Urethral disease         51                         (0.2)                      51      (0.2)    \>0.999

LUTS-BPH, lower urinary tract symptoms---benign prostate hyperplasia; COPD, chronic obstructive pulmonary disease.

Among the 44,620 sampled individuals, 1,867 (4.18%) developed IH during the 10 years of follow-up, of which 1,303 (5.84%) among men with LUTS-BPH and 735 (2.53%) among men without LUTS-BPH ([Fig 1](#pone.0234329.g001){ref-type="fig"}). The incidence rate was 7.65 per 1000 persons and 3.30 per 1000 person years respectively. Subjects with LUTS-BPH were more likely to develop IH than were subjects without LUTS-BPH (crude HR = 2.32; 95% CI = 2.10--2.56, p-value = \<0.001) as shown in [Table 2](#pone.0234329.t002){ref-type="table"}. The risk was still increased after adjusting for age and comorbidities (adjusted HR = 2.25, 95% CI = 2.04--2.49, p-value \< 0.001). After age stratification, the adjusted HR for subsequent IH was 2.27 (95% CI = 2.05--2.50) in those aged equal to or more than 40 years of age, which showed significant difference (p-value \<0.001), and 1.48 (95% CI = 0.59--3.71) in those aged less than 40 years of age, which showed no significant difference (p-value = 0.402). ([Table 2](#pone.0234329.t002){ref-type="table"})

![Lower urinary tract symptoms---benign prostatic hyperplasia and the risk of subsequent inguinal hernia.\
Individuals with lower urinary tract symptoms---benign prostatic hyperplasia were more likely to develop inguinal hernia than those without lower urinary tract symptoms---benign prostatic hyperplasia.](pone.0234329.g001){#pone.0234329.g001}

10.1371/journal.pone.0234329.t002

###### The risk of inguinal hernia between LUTS-BPH (-) cohort and LUTS-BPH(+) cohort (N = 44,620).

![](pone.0234329.t002){#pone.0234329.t002g}

                                  Crude model         Adjusted model[^a^](#t002fn002){ref-type="table-fn"}                       
  ----------------- ------ ------ ------------------- ------------------------------------------------------ ------------------- ---------
  Overall                                                                                                                        
  LUTS-BPH(-)       564    3.30   REF.                                                                       REF.                
  LUTS-BPH(+)       1303   7.65   2.32 (2.10--2.56)   \<0.001                                                2.25 (2.04--2.49)   \<0.001
  AGE\<40, y/o                                                                                                                   
  LUTS-BPH(-)       8      1.31   REF.                                                                       REF.                
  LUTS-BPH(+)       11     1.84   1.41 (0.57--3.51)   0.459                                                  1.48 (0.59--3.71)   0.402
  AGE\> = 40, y/o                                                                                                                
  LUTS-BPH(-)       556    3.37   REF.                                                                       REF.                
  LUTS-BPH(+)       1292   7.87   2.33 (2.11--2.58)   \<0.001                                                2.27 (2.05--2.50)   \<0.001

LUTS-BPH, lower urinary tract symptoms---benign prostate hyperplasia; CI, confidence interval; REF., reference.

^a^Adjusted for age and comorbidities.

[Table 3](#pone.0234329.t003){ref-type="table"} shows the average follow-up duration and average occurrence duration of new onset IH between individuals with and without LUTS-BPH. The average follow-up durations in the LUTS-BPH(-) and LUTS-BPH(+) cohort (mean ± SD) were 7.67 ± 2.81 and 7.63 ± 2.76 years, respectively. There was no significant difference between them. The durations from index date to the date of new onset IH diagnosis in the LUTS-BPH(-) and LUTS-BPH(+) cohorts (mean ± SD) were 4.44 ± 2.75 and 4.02 ± 2.83 years, respectively, which showed significant difference (p-value \<0.003).

10.1371/journal.pone.0234329.t003

###### Average follow-up duration and average occurrence duration of new onset inguinal hernia between LUTS-BPH (-) and LUTS-BPH(+) cohort (N = 44,620).

![](pone.0234329.t003){#pone.0234329.t003g}

                Follow-up duration (years)   New onset IH (years)                           
  ------------- ---------------------------- ---------------------- ------- ------ -------- -------
  LUTS-BPH(-)   7.67                         (2.81)                         4.44   (2.75)   
  LUTS-BPH(+)   7.63                         (2.76)                 0.167   4.02   (2.83)   0.003

LUTS-BPH, lower urinary tract symptoms---benign prostate hyperplasia; SD, standard deviation; IH, inguinal hernia.

Discussion {#sec011}
==========

Despite many experts attempting to explain the association between LUTS-BPH and hernia formation, the relation between LUTS-BPH and IH might be more complicated and intertwined because both are affected by aging \[[@pone.0234329.ref011], [@pone.0234329.ref036]\]. In this population-based cohort study, we used Taiwanese men to explore the association between LUTS-BPH and the subsequent risk of IH. To our knowledge, this is currently the largest cohort study focusing on the relationship between LUTS-BPH and IH (n = 44,620, including 1,867 men who developed IH patients). We found that preceding LUTS-BPH is an independent risk factor for subsequent IH after controlling for potential confounders (adjusted HR = 2.25, 95% CI = 2.04--2.49, p-value \< 0.001). The relationship was prominent in individuals equal to or more than 40 years of age (HR = 2.27, 95% CI = 2.05--2.50, p-value\<0.001). Additionally, average duration from diagnosis of LUTS-BPH to discover IH was 4.02 years, which is much shorter than patients without LUTS-BPH.

Our findings are supported with the results of the study published on 2011 by Reis et al, who were the first to investigate the correlation between the presence of IH and LUTS-BPH through quantification by the International Prostate Symptom Score (IPSS) \[[@pone.0234329.ref026]\]. The IPSS includes seven questions for storage symptoms (frequency, urgency and nocturia) and voiding symptoms (incomplete emptying, intermittency, weak stream and straining) and indicates how LUTS-BPH affects urine void \[[@pone.0234329.ref037]\]. The study retrospectively categorized 52 patients into one group of LUTS-BPH with IH and one group of LUTS-BPH without IH. The IPSS was significantly higher in those with LUTS-BPH and IH. This provides a good hint about LUTS-BPH being related to IH. Significant increase of PVR in the group of LUTS-BPH and IH also supports the findings \[[@pone.0234329.ref026]\]. Another study showed that the prevalence of significant LUTS was found to be 48% in patients with IH \[[@pone.0234329.ref038]\], which also assists our results. Interestingly, a prospective controlled clinical trial analyzed the changes of uroflowmetric parameters following IH repair surgery, which demonstrated that IH repair could significantly affect the maximum flow rate and PVR on postoperative day 1. They concluded that we should identify patients suitable for preoperative treatment before IH repair to reduce the possibility of urinary adverse effects \[[@pone.0234329.ref039]\].

The mechanisms that might explain the increased risk of subsequent IH in patients with LUTS-BPH are unclear. One possible hypothesis is that LUTS-BPH patients have to push or strain to begin urination, which might lead to an increase in intra-abdominal pressure \[[@pone.0234329.ref037]\]. Other symptoms, such as frequency, intermittency, incomplete emptying and weak stream may also result in raising intra-abdominal pressure \[[@pone.0234329.ref037]\]. An extension of these findings recommend that increased intra-abdominal pressure, over time, provides a causal link between benign prostatic hyperplasia, low urinary tract symptoms and inguinal hernia \[[@pone.0234329.ref037]\].

However, Sentürk achieved contrary conclusions through IPSS in investigating the relation between LUTS-BPH and IH \[[@pone.0234329.ref025]\]. Per a similar experiment, the patients above 50 years were divided into two groups, LUTS-BPH with IH (n = 50) and LUTS-BPH without IH (n = 50). There was no significant difference in IPSS between the two groups, but prostate volume was significantly enlarged in patients with LUTS-BPH and IH. The result may be accounted for by poor correlation between prostate size and LUTS, and small population size as well. In addition, subclinical inguinal hernia is also an obstacle for us to speculate that LUTS-BPH lead to subsequent IH. A prospective study showed that undiagnosed IH was found accidently in 13% of patients when undergoing laparoscopic surgery \[[@pone.0234329.ref040]\].

Both LUTS-BPH and IH are not malignant diseases but they indeed impact quality of life. Most men diagnosed with LUTS-BPH suffer from annoying urinary dysfunction and make regular visit to an outpatient clinic for long-term medical control and even surgical intervention \[[@pone.0234329.ref041]\]. On the contrary, IH may be ignored because it is painless in most circumstances; however, it becomes enlarged and leads to pain over time. Once the intra-abdominal contents become trapped within an inguinal sac, the incarceration or strangulation of intestines might occur. The latter can be fetal and needs surgery immediately \[[@pone.0234329.ref001]\]. It is noteworthy that our study showed the duration of follow-up since diagnosis of LUTS-BPH to notice the presence of IH is 4.02 years. This reminds clinicians to perform careful groin examinations to discover possible hernia formation in patients visiting for LUTS-BPH medication, thereby allowing progressive inguinal hernia to be treated in a more timely manner.

There are several limitations in our study. Firstly, it is a retrospective analysis. Further studies could consider arranging prospective studies to improve the findings. Secondly, analyzed data was retrieved from the Taiwanese National Health Insurance database, which is a coding system rather than a medical chart review, so clinical information like uroflow data, prostate volume, IPSS, body mass index or detailed treatments could not be determined. Thirdly, although we enrolled as many as possible confounders, some factors were not included in our study, such as smoking status, past history of abdominal surgeries, educational status and income. Fourthly, our population is of majority Han Chinese ethnicity, which may not be the same as other ethnic groups. Fifthly, the censoring in this dataset should be considered because some patients with LUTS-BPH and IH might not have visited a doctor. Sixthly, our study did not use the history of prescriptions to enhance the diagnosis of LUTS-BPH; however, patients with LUTS-BPH might not take medications, and this means we could include those patients with minor LUTS in our study. Finally, we did not restrict the age of patients to be older than 40 years old, which resulted in 699 LUTS-BPH patients younger than 40 years old being enrolled in our study. As we known, lower urinary tract symptoms prevalence in men younger than 40 years old was around 8% \[[@pone.0234329.ref042]\], so it is worthy of studying whether the chance of getting IH is also increasing in this group of patients. In spite of the limitations mentioned above, this is a large-scale study composed of two groups with similar characteristics and comorbidities. This is also the first nationwide study investigating the relationship between LUTS-BPH and hernia formation in a Taiwanese population. The long-term observational data would assist physicians in keeping IH in mind when treating LUTS-BPH patients.

Conclusion {#sec012}
==========

Apart from aging, LUTS-BPH is associated with subsequent IH formation. Clinicians should pay attention to groin examination for those men with LUTS-BPH and initiate long-term follow-up.

The authors would like to acknowledge the Department of Internal Medicine and the Statistical Analysis Laboratory in the Department of Medical Research at Kaohsiung Medical University Hospital.
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RESPONSE: This is a really good point and we will explain it more clearly in the manuscript. In our country, a diagnosis of BPH was based on the doctor's judgements, either by clinical symptoms and/or digital examinations. There was no unanimous guidelines. So, it's difficult to know the definite reasons why these patients \<40 were diagnosed as BPH. There is a high chance that patients with voiding symptoms are coded BPH, but we did not have further information. We will add this limitation into our discussion and we revised the related paragraph as below: "We used the ninth revision of the International Classification of Diseases (ICD9) codes 600.XX to identify the BPH cohort. A diagnosis of BPH was based on the clinical symptoms and/or digital examinations by physicians." (line 1 to 4, revised manuscript page 7)

Limitations: "Finally, we did not restrict the age of patients to be older than 40 years old, which resulted in 699 BPH patients younger than 40 years old being enrolled in our study. As we known, lower urinary tract symptoms prevalence in men younger than 40 years old was around 8% \[41\], and it is worthy of studying whether the chance of getting IH is also increasing in this group of patients." (line 6 to 10, revised manuscript page 17)

3\. Last but not least, I have some difficulty to understand that the 14 days difference in diagnoses can have a pathophysiological meaning; can you slightly more elaborate on the \'sequential\' -hypothesis?

RESPONSE: I apologized that I did not make the table 3 more clear. The 14 days difference is for follow-up duration, which means the mean follow-up duration for BPH(-) cohort (N=22,310) was 7.67 years and for BPH(+) cohort (N=22,310) was 7.63, and there was no significant difference between them (P=0.167).

The duration from index date to the diagnosis of inguinal hernia was listed in the right side of Table 3. The mean duration for BPH(-)IH(+) patients (N=564) was 4.44 years and for BPH(+)IH(+) patients (N=1303) was 4.02 years, which was significant different (P=0.003). This finding could give us another evidence that BPH/LUTS might not only affect the incidence of IH, but also shorten the duration of IH formation.

We revised this paragraph as : "The average follow-up durations in the BPH(-) and BPH(+) cohort (mean ± SD) were 7.67 ± 2.81 and 7.63 ± 2.76 years, respectively. There was no significant difference between them. The durations from index date to the date of new onset IH diagnosis in the BPH(-) and BPH(+) cohorts (mean ± SD) were 4.44 ± 2.75 and 4.02 ± 2.83 years, respectively, which showed significant difference (p-value \<0.003)." (line 1 to 7 from the bottom, revised manuscript page 11)

Reviewer 1 Comments:

1\. Although the authors included some potential confounders, there are still some more such as education status and income. It is possible that patients with high educational level or high income are likely to seek healthcare due to BPH or IH. They should discuss this limitation.

RESPONSE: Thank you for this suggestion. We added this into the limitations and revised as follows: "Thirdly, although we enrolled as many as possible confounders, some factors were not included in our study, such as smoking status, past history of abdominal surgeries, educational status and income." (line 1-4 from the bottom, revised manuscript page 16)

2\. This study included male patients over 20 years old. There were 699 patients less than 40 years old with BPH. I think that these patients did not have BPH and the authors should change the inclusion criteria.

RESPONSE: This is a really good point and we will explain it more clearly in the manuscript. The reason why we enrolled male patients over 20 years old, instead of 40 years old, was due to lower urinary tract symptoms prevalence in men younger than 40 years old was around 8% \[41\], and it is worthy of studying whether the chance of getting IH is also increasing in this group of patients. Besides, it is hard to change the inclusion criteria at this stage, because the study cohort and the matched cohort need to be re-selected (ratio: 1:1), and all tables and figures need to be changed. In the manuscript, we try to minimize the flaw and divided patients by age \<40 and age \>= 40, which could show the conditions of each age-group. We will add this into our limitations.

Limitations: "Finally, we did not restrict the age of patients to be older than 40 years old, which resulted in 699 BPH patients younger than 40 years old being enrolled in our study. As we known, lower urinary tract symptoms prevalence in men younger than 40 years old was around 8% \[41\], and it is worthy of studying whether the chance of getting IH is also increasing in this group of patients." (line 6 to 10, revised manuscript page 17)

Reviewer 2 Comments:

1\. I advise to send this article to statistical/epidemiological review (confounding factors, sample size, methods, etc.)

RESPONSE: Thank you for this suggestion. I sent this article to epidemiological review and we revised the manuscript by their suggestions. Here we listed some key points they suggested:

\- Confounding factors: Thirdly, although we enrolled as many as possible confounders, some factors were not included in our study, such as smoking status, past history of abdominal surgeries, educational status and income." (line 1-4 from the bottom, revised manuscript page 16)

\- Sample size: Normally you select more controls, at least a 3:1 ratio. However, this is not possible to change at this stage.

\- Methods: Use the term of cohort study with a matched comparison cohort instead of case-control study. "This is a population-based cohort study, including men with BPH and a matched comparison cohort of men without BPH." (line 1-2 from the bottom, revised manuscript page 6)

\- Provide more information about start and end of follow-up. "All medical claims of men aged 20 and above from 1997-2013 year were collected." (line 1, revised manuscript page 7)

\- All men were followed from the date of diagnosis until death, emigration or end of follow-up (31 December 2013), whichever event came first. (line 3-4 from the bottom, revised manuscript page 7)

2\. The objective in introduction is clearly stated, but it is so long.

RESPONSE: Thank you for this suggestion. We revised the introduction to make it shorter.

3\. Profound statistics. Have the authors been counseled by statistical professionals and/or epidemiologists?

RESPONSE: as comment 1.

4\. Are there any confounding factors like body mass index, prior abdominal surgery? Have these confounding factors been excluded?

RESPONSE: Thank you for this suggestion. We had obesity as one of the confounding factors, instead of body mass index. We did not have the data of body mass index because our database was from coding system rather than a medical chart review. Clinical information like uroflow data, prostate volume and body mass index could not be determined. We will add this into limitation. About the abdominal surgery, the well-documented risk factor of inguinal hernia was radical prostatectomy. So we excluded the patients who had received radical prostatectomy before the index date. We did not have the data of other abdominal surgeries, so we also added into our limitation. "Thirdly, although we enrolled as many as possible confounders, some factors were not included in our study, such as smoking status, past history of abdominal surgeries, educational status and income." (line 1-3 from the bottom, manuscript page 16)

5\. The authors should mention an interesting clinical trial; Unal Y, Kilinc MF. Does inguinal hernia repair affect uroflowmetric parameters? A prospective controlled clinical trial. Low Urin Tract Symptoms. 2019 May;11(3):99-103. doi: 10.1111/luts.12239. Epub 2018 Aug 31.

RESPONSE: Thank you for this suggestion. We revised the manuscript. "Interestingly, a prospective controlled clinical trial analyzed the changes of uroflowmetric parameters following IH repair surgery, which demonstrated that IH repair could significantly affect the maximum flow rate and PVR on postoperative day 1. They concluded that we should identify patients suitable for preoperative treatment before IH repair to reduce the possibility of urinary adverse effects \[38\]" (line 9 to 14, manuscript page 14)

CONCLUDING REMARKS: Again, thank you for giving us the opportunity to strengthen our manuscript with your valuable comments and queries. We have worked hard to incorporate your feedback and hope that these revisions persuade you to accept our submission.

Sincerely,

Corresponding Author

JIUN-HUNG GENG
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Click here for additional data file.
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Benign Prostatic Hyperplasia May Increase the Risk of Subsequent Inguinal Hernia in a Taiwanese Population: A Nationwide Population-Based Cohort Study

PLOS ONE

Dear Dr. Geng,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

Now you have explained that: 'A diagnosis of BPH was based on the clinical symptoms and/or digital examinations by physicians', I ask you to consider changing the title to: 'Lower Urinary Tract Symptoms -Benign Prostatic Hyperplasia May Increase the Risk of Subsequent Diagnosis of Inguinal Hernia in a Taiwanese Population: A Nationwide Population-Based Cohort Study'. Where you mention lower urinary tract symptoms, you can add LUTS as the abbreviation and change all BPH for LUTS-BPH where appropriate. You may consider referring to: Lee CL, Kuo HC. Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia. Ci Ji Yi Xue Za Zhi. 2017;29(1):6--11. doi:10.4103/tcmj.tcmj_3\_17' but also to ref 36. With my excuse for overlooking this earlier, I ask you also to remove reference 39 and replace that with a reference to 36. 39 is not making this conclusion (and the discussion about the specific medication is irrelevant for your study and hypothetical/speculative (and has in many subsequent studies demonstrated not to have any effect on outflow obstruction)

==============================

We would appreciate receiving your revised manuscript by Jun 07 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Peter F.W.M. Rosier, M.D. PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Because the authors answer my questions very well, I think that this article should be published in this journal.

Reviewer \#2: Thanks to the authors for their efforts to publish their manuscript.

All my comments have been addressed.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Tsuyoshi Majima

Reviewer \#2: Yes: MF Kilinc

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0234329.r004

Author response to Decision Letter 1

20 May 2020

Dear editor and reviewers:

We are very grateful to your comments for the manuscript.

To facilitate your review of our revisions, the following is a point-by-point response to the questions and comments delivered in your letter dated 4/24/2020.

Editor's Suggestions:

1\. Consider changing the title to: 'Lower Urinary Tract Symptoms -Benign Prostatic Hyperplasia May Increase the Risk of Subsequent Diagnosis of Inguinal Hernia in a Taiwanese Population: A Nationwide Population-Based Cohort Study'.

\# RESPONSE: Thank you for this suggestion. We revised the title of our study. (Page 1, line 1)

2\. Where you mention lower urinary tract symptoms, you can add LUTS as the abbreviation and change all BPH for LUTS-BPH where appropriate. You may consider referring to: Lee CL, Kuo HC. Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia. Ci Ji Yi Xue Za Zhi. 2017;29(1):6--11. doi:10.4103/tcmj.tcmj_3\_17' but also to ref 36.

\# RESPONSE: Thank you for this suggestion. We revised our manuscript by following the recommended instructions. Please checked the file of "revised manuscript with tract changes." We extracted some corrections here "Benign prostatic hyperplasia (BPH) is one of the most common causes of male lower urinary tract symptoms (LUTS) and occurs with aging \[22, Lee CL, Kuo HC\]. As LUTS-BPH progresses despite medical treatment, post void residual (PVR) and urinary tract infection can be identified requiring appropriate surgical intervention. (Page 5, line7-10)

3\. With my excuse for overlooking this earlier, I ask you also to remove reference 39 and replace that with a reference to 36. 39 is not making this conclusion (and the discussion about the specific medication is irrelevant for your study and hypothetical/speculative (and has in many subsequent studies demonstrated not to have any effect on outflow obstruction)

\# RESPONSE: Thank you for this suggestion. We removed reference 39 and replace that with a reference to 36.

CONCLUDING REMARKS: Again, thank you for giving us the opportunity to strengthen our manuscript with your valuable comments and queries. We have worked hard to incorporate your feedback and hope that these revisions persuade you to accept our submission.

Sincerely,

Corresponding Author

JIUN-HUNG GENG

Kaohsiung Municipal Hsiao-Kang Hospital

100 Shih-Chuan 1st Road, Kaohsiung 807, Taiwan

Telephone: +886-7-3208212

E-mail: <u9001090@hotmail.com>
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Lower Urinary Tract Symptoms - Benign Prostatic Hyperplasia May Increase the Risk of Subsequent Inguinal Hernia in a Taiwanese Population: A Nationwide Population-Based Cohort Study

PONE-D-20-01358R2

Dear Dr. Geng,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Peter F.W.M. Rosier, M.D. PhD

Academic Editor

PLOS ONE
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Lower Urinary Tract Symptoms - Benign Prostatic Hyperplasia May Increase the Risk of Subsequent Inguinal Hernia in a Taiwanese Population: A Nationwide Population-Based Cohort Study

Dear Dr. Geng:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Peter F.W.M. Rosier

Academic Editor

PLOS ONE
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